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S U M M A R Y
Objectives: Stenotrophomonas maltophilia is a recently identiﬁed nosocomial pathogen in Malaysia.
Despite limited pathogenicity, its rate of isolation has increased in recent years. The aim of this study was
to investigate the antibiotic susceptibility patterns, antibiotic resistance determinants, and the
epidemiology of S. maltophilia at the largest tertiary care hospital in Malaysia.
Methods: This study was carried out from January to December 2008. Sixty-four S. maltophilia isolates
were investigated for their antibiotic susceptibility patterns by disk diffusion test and E-test. The
antibiotic resistance mechanism for trimethoprim–sulfamethoxazole (TMP–SMX) was assessed by PCR
for sul1, sul2, qac/smr, and class 1 integrons in general. Epidemiological relatedness among isolates was
determined by pulsed-ﬁeld gel electrophoresis (PFGE).
Results: The highest number of S. maltophilia infections was observed in the intensive care unit (ICU)
(n = 13; 20.3%), while the lowest number of infections was seen in the neurology, psychiatric, and
dermatology wards (each n = 1; 1.6%). All isolates were susceptible to minocycline. One isolate was
resistant to TMP–SMX with a minimum inhibitory concentration (E-test) >32 mg/l. The strain carried
the sul1 gene and class 1 integron. None of the isolates were positive for the qac/smr genes. Although the
data suggest the potential for patient to patient transmission, most of the S. maltophilia strains showed
unrelated PFGE patterns and were considered to be genetically diverse.
Conclusion: The increasing number of S. maltophilia isolates seen in the ICU, their resistance to mainstay
antibiotics, their genetically diverse nature, and possible cross-transmission within the hospital,
strongly underscores the need for continuous surveillance for S. maltophilia in the hospital setting.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Stenotrophomonas maltophilia, previously known as Pseudomo-
nas maltophilia or Xanthomonas maltophilia, is found ubiquitously
in nature. This opportunistic bacterial species is now an emerging
nosocomial pathogen. Its intrinsic or acquired resistance to most
antibiotics and its ability to colonize the surfaces of medical
devices make S. maltophilia a potentially dangerous pathogen,
especially among patients with prolonged hospitalization, malig-
nancy, immune suppression, and breakdown of the mucocutane-
ous defense barriers (e.g., following catheterization, artiﬁcial
implantation, tracheotomy, or peritoneal dialysis).1 In severely* Corresponding author. Tel.: +60 3 89472507; fax: +60 3 89413802.
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http://dx.doi.org/10.1016/j.ijid.2012.04.004ill patients, S. maltophilia causes a wide range of infections,
including nosocomial pneumonia, bacteremia, pulmonary
infections, urinary tract infections, wound infections, skin and
soft tissue infections, meningitis, and endocarditis.1–3 Thus S.
maltophilia is a highly versatile pathogen.
The management of S. maltophilia infections represents a great
challenge to clinicians due to problems with in vitro susceptibility
testing, a lack of clinical trials to determine optimal therapy, and its
intrinsic resistance to a plethora of antimicrobial agents, which
severely limits the effectiveness of commonly used empiric
antimicrobial therapies.4,5
Trimethoprim–sulfamethoxazole (TMP–SMX) is the recom-
mended drug for the treatment of S. maltophilia infections based on
in vitro susceptibility data, and a favorable outcome has been
observed in patients treated with these agents.1,4 TMP–SMX is
reported to be more effective than the new ﬂuoroquinolones such
as levoﬂoxacin and gatiﬂoxacin.6 However, during recent years,ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Distribution of Stenotrophomonas maltophilia isolates based on the ward of isolation
(N = 64)
Ward Number of isolates (%)
Neurosurgery 9 (14.1%)
Anesthesiology/ICU 13 (20.3%)
General medicine 9 (14.1%)
Pediatric 10 (15.6%)
Orthopedic 3 (4.7%)
Urology and nephrology 12 (18.8%)
Surgery 3 (4.7%)
Respiratory institute 2 (3.1%)
Neurology 1 (1.6%)
Psychiatric 1 (1.6%)
Radiotherapy and oncology 1 (1.6%)
ICU, intensive care unit.
Table 2
Distribution of Stenotrophomonas maltophilia isolates based on the specimen type
(N = 64)
Type of specimen Number of isolates (%)






Peritoneal ﬂuid 1 (1.6%)
Bronchoalveolar lavage 1 (1.6%)
Unknown 1 (1.6%)
CSF, cerebrospinal ﬂuid.
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resistant S. maltophilia, with a prevalence ranging from 3.8% in
Latin America, North America, and Europe to 28.3% in Turkey.7,8
Several studies investigating the molecular epidemiology of
S. maltophilia have shown clinical isolates to be genetically
diverse.7,9
In Malaysia, the occurrence of S. maltophilia infection has
increased over recent years, from less than 50 cases in 2003 to
more than 150 in 2007 at the largest tertiary care hospital.
Unfortunately, no published data are available on the antibiotic
susceptibility patterns, antibiotic resistance mechanisms, or the
genetic diversity and epidemiology of Malaysian S. maltophilia
strains. As the management of S. maltophilia infections is challeng-
ing, understanding the characteristics of local strains is necessary for
the development of new strategies for the prevention or prophylaxis
of such infections. Therefore the aim of the present study was to
investigate the antibiotic resistance patterns and genotypes of S.
maltophilia isolates from clinical specimens in Malaysia.
2. Methods
2.1. Clinical setting and bacterial strains
S. maltophilia isolates were collected between January and
December 2008 at the largest tertiary care hospital in Malaysia,
where an average of 100 S. maltophilia isolates are isolated
annually. Specimen types and the ward of isolation were recorded.
Among isolates collected from January to December 2008, 64
positive cultures from 56 patients (isolate numbers 2 and 3 from
patient 2; 6 and 7 from patient 7; 14, 15, 18, and 23 from patient
14; 47 and 48 from patient 47; 41, 42, and 46 from patient 41)
were available for investigation at our laboratory (Medical
Microbiology, Universiti Putra Malaysia, Serdang). The isolates
were phenotypically conﬁrmed as S. maltophilia by API 20 NE
(bioMe´rieux, Marcy l’Etoile, France), the presence of lavender
green colonies on blood agar plates, and the production of DNase.
All isolates previously identiﬁed to the species level by phenotypic
methods were reconﬁrmed molecularly by species-speciﬁc PCR10
and stored at 80 8C in Luria–Bertani broth supplemented with
20% glycerol. S. maltophilia ATCC 13637 was used as the reference
strain.
2.2. Antibiotic susceptibility testing
Susceptibility to antimicrobial agents was determined by the
disk diffusion method. Data obtained for isolates sensitive or
resistant to ticarcillin–clavulanic acid, ceftazidime, minocycline,
and levoﬂoxacin were interpreted in accordance with the Clinical
and Laboratory Standard Institute guidelines (CLSI).11 Minimum
inhibitory concentration (MIC) values for TMP–SMX were deter-
mined by E-test (bioMe´rieux, Marcy l’Etoile) as per CLSI guide-
lines.11
2.3. Integrons and sulfonamide and quaternary ammonium
compound (QAC) resistance genes PCR
The presence of class 1 integrons, the associated sulfonamide
resistance gene (sul1), and QAC (antiseptic) resistance genes qac/
smr were screened in the S. maltophilia isolates with primers and
PCR conditions described previously.12–14 Template DNA for PCR
was prepared by boiling 5–10 colonies of S. maltophilia in 25 ml of
sterile water for 10–12 min. The boiled suspension was snap-
cooled and centrifuged at 10 000 g for 5 min; the supernatant or
boiled cell lysate was used as the PCR template. Ampliﬁcation
reactions of 20 ml were prepared with 0.5 ml of template DNA,
5 pmol of forward and reverse primers, and 5 ml of PCR master mix(i-DNA Biotechnology (M) Sdn Bhd, Malaysia). The ampliﬁed
products were sequenced and further analyzed by GenBank BLAST
analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
2.4. Molecular typing of S. maltophilia isolates by pulsed-ﬁeld gel
electrophoresis (PFGE)
PFGE macro-restriction analysis of isolates was performed
essentially by the method of Denton and Kerr.1 S. maltophilia DNA
was digested with SpeI restriction endonuclease (Fermentas, Axon
Scientiﬁc, Malaysia) using XbaI-digested Salmonella Braenderup
H2812 DNA as a size and gel normalization standard. Electropho-
resis was performed in 1% agarose (Seakem Gold, Lonza, Rockland,
ME, USA) on a CHEF DRII apparatus (BioRad Laboratories) at 6 V/
cm, with switching linearly ramped from 5 to 35 s for 22 h at 14 8C.
Images of ethidium bromide-stained gels were captured electron-
ically and compared (UPGMA, Dice coefﬁcient) using Bionumerics
v6.6 software (Applied Maths, Sint-Martens-Latem, Belgium).
PFGE analysis was repeated in triplicate to conﬁrm reproducibility
of the banding patterns.
3. Results
3.1. Distribution of S. maltophilia among the different wards and
clinical sources
S. maltophilia strains were isolated from patients admitted to
various wards, as listed in Table 1. The highest number of S.
maltophilia infections was observed in the ICU (n = 13; 20.3%), and
the lowest number was seen in the neurology, psychiatric, and
dermatology wards (each n = 1; 1.6%).
The largest number of isolates were obtained from tracheal
aspirates (n = 25, 39.1%), while only one isolate (1.6%) was
obtained from peritoneal ﬂuid and one (1.6%) from bronchoalveo-
lar lavage (Table 2).
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All isolates were susceptible to minocycline. Resistance was
observed for ceftazidime (56.3%), ticarcillin–clavulanic acid
(31.3%), and levoﬂoxacin (32.8%). One isolate was resistant to
TMP–SMX, with an E-test MIC value >32 mg/l; this isolate
possessed the sul1 gene and class 1 integrons and was also
resistant to ceftazidime. None of the isolates carried qac/smr genes.Figure 1. The PFGE proﬁle of 63 Stenotrophomonas maltophilia isolates isolated in di3.3. Integrons and sulfonamide and quaternary ammonium
compound (QAC) resistance
Among the 64 isolates screened for class 1 integrons and sul1
and qac/smr genes, one isolate (isolate 4) phenotypically
resistant to TMP–SMX was positive for integron and sul
genes. All of the isolates were negative for antiseptic resistance
genes.fferent wards and from different clinical sources, showing 59 distinct patterns.
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In general, the PFGE analysis (Figure 1) revealed the S.
maltophilia isolates to be unrelated; 63 isolates yielded 59 distinct
patterns. Multiple isolates from the same patient (i.e., isolates 14,
15, 18, and 23 from patient 14; 47 and 48 from patient 47), the
same body site, or recovered at different times over the course of
the same admission, were found to be genetically diverse,
implicating more than one strain in the infection. However, there
were instances where indistinguishable isolate pairs were recov-
ered from the same or different body sites of patients over the
course of the same admission (e.g., isolates 2 (peritoneal ﬂuid) and
3 (blood) from patient 2; isolates 6 and 7 (both from pus) from
patient 6). Isolates that were homologous (e.g. isolates 14 and 19)
were also cultured from different patients on different wards.
4. Discussion
In the current study, S. maltophilia strains isolated over a 1-year
period at the largest public hospital of Kuala Lumpur were
examined. As noted by others,15,16 S. maltophilia was found as a
high-risk nosocomial pathogen in the ICU (Table 1). This
unfortunate trend is reinforced by the generally weak and
immune-compromised state of ICU patients and other factors
including increased length of stay, mechanical ventilator support,
and inadequate empiric antibiotic therapy.
With regard to antibiotic susceptibility, all isolates were found
to be susceptible to minocycline. However, for the other antibiotics
tested the susceptibility varied from 20% to 68%. An extensive
review by Nicodemo and Paez17 demonstrated S. maltophilia
susceptibility to minocycline to be >80%, while the susceptibility
to ticarcillin–clavulanic acid, the second therapeutic option, was
>70%. Gesu et al.18 in an in vitro study reported S. maltophilia
susceptibility to levoﬂoxacin at 85.5%. Since S. maltophilia isolates
in Malaysia are susceptible to minocycline and resistance to
levoﬂoxacin and ticarcillin–clavulanic acid is low, these antibiotics
are considered good therapeutic agents against infection in this
region, as also suggested by Nicodemo and Paez.17
With less than 5% resistance, TMP–SMX remains the therapy of
choice against S. maltophilia worldwide.19 However, a 6-year study
has reported increasing (84%) resistance to TMP–SMX.20 In the
current study, only one of the 64 isolates tested (1.6%), a strain
isolated from a CSF sample, showed resistance to TMP–SMX, with a
MIC >32 mg/l. This result is in accordance with that of Barbolla
et al.21 who reported less than 1% resistance to TMP–SMX.
Although TMP–SMX is the ﬁrst choice for the treatment of S.
maltophilia infections, the combination of TMP–SMX with ticar-
cillin–clavulanate, or TMP–SMX plus tobramycin, or TMP–SMX
plus ciproﬂoxacin is reported to be more effective with a more
pronounced bactericidal acitivity.19,21–23
Several studies performed on S. maltophilia isolates have shown
that sul1genes associated with class 1 integrons are the major
mechanism of TMP–SMX resistance. In a survey of 55 S. maltophilia
isolates (30 sensitive and 25 resistant) by PCR, Toleman et al.19
found that 17 of 25 resistant isolates possessed the sul1 gene and
class 1 integrons. Similarly Chang et al.24 reported that 26 out of
100 (26%) S. maltophilia isolates were resistant to TMP–SMX, with
81% sul1-positive and carrying class 1 integron. In another study in
Taiwan,25 an increased class 1 integron presence in S. maltophilia
isolates (15 out of 17, 88%) was demonstrated, with 73% (n = 11)
carrying the sul1 gene. These data underscore the high prevalence
of class 1 integrons in TMP–SMX-resistant clinical isolates of S.
maltophilia.
Resistance to TMP–SMX has also been be associated with the
presence of QAC resistance genes such as smr, qacF, and qacH,
which are also harbored by class 1 integrons.24 Chang et al.24 haveshown that QAC resistance genes (including qac/smr carried on a
class 1 integron) are signiﬁcantly associated with resistance to
TMP–SMX in Taiwan. A high incidence of QAC resistance is favored
when biocides containing QACs are used above recommended
concentrations for treatment and decontamination in hospitals.26
Despite the routine use of antiseptics such as chlorhexidine (4%)
for patients and 70% alcohol for surface disinfection at the large
tertiary hospital in the current study, no resistance to QAC
compounds was detected in S. maltophilia isolates.
In the current study, 63 S. maltophilia isolates were available for
epidemiological analysis by PFGE (Figure 1) with results demon-
strating a high level of diversity among isolates despite similar
body sites and wards of isolation. These results are in accordance
with earlier studies demonstrating an elevated genetic diversity in
S. maltophilia isolates even when recovered from the same
hospital.27,28 For example, Valdezate et al.29 found ﬁve phylogenic
clusters with diversity ranging from low (28.0%) to high similarity
(80.0%). Although the isolates examined here exhibited high
heterogeneity, the recovery of homologous isolates from different
patients on different wards (e.g., isolates 14 and 19, 21 and 23, and
35 and 38) shows the possibility of transmission within the
hospital, which in the future could certainly include TMP–SMX-
resistant strains. A study by Jumaa et al.30 found that 16 out of 21 S.
maltophilia isolates had distinct PFGE patterns, although three
clusters with more than 95% similarity were detected, two isolated
from the same patient while the other contained two strains
isolated from two different patients from different wards and at
different time points. These ﬁndings further reinforce the
conclusion that while multiple sites (routes) of S. maltophilia
acquisition are more common, cross-transmission is also possible.
In conclusion, the results of the current study show that
minocycline and TMP–SMX continue to be the best therapeutic
options for the treatment of S. maltophilia infections in the
Malaysian setting, although resistance to the mainstay antibiotic
TMP–SMX was observed in one isolate. Epidemiologically, S.
maltophilia strains are genetically diverse and their emergence is
common. However, the isolation of homologous isolates from
different patients and different wards demonstrates that cross-
transmission of strains across wards is also possible. Hence,
management of these infections is problematic as strains may not
behave uniformly and transmission may include multiple drug-
resistant isolates. These results support efforts directed towards
continuous surveillance for antimicrobial drug resistance and
epidemiological monitoring, which may act as early warning
systems for predicting resistance and preventing outbreaks.
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